Targeted Therapy and Immunotherapy in Oncology
Targeted Therapy and Immunotherapy in Oncology ( 5 Questions)
A nurse is caring for a client who is receiving rituximab, a monoclonal antibody, as part of targeted therapy for nonHodgkin's lymphoma. The nurse should monitor the client for which of the following adverse effects of this drug?
Infusion reactions and allergic reactions are common and potentially serious adverse effects of rituximab, a monoclonal antibody that binds to the CD20 antigen on the surface of B lymphocytes and causes their destruction. Rituximab is used to treat nonHodgkin's lymphoma, a type of cancer that affects the lymphatic system. Infusion reactions can occur during or shortly after the administration of rituximab and may include fever, chills, rigors, hypotension, dyspnea, bronchospasm, angioedema, and anaphylaxis. Allergic reactions can occur within hours or days after the infusion and may include rash, urticaria, pruritus, and serum sickness. The nurse should monitor the client's vital signs, oxygen saturation, and symptoms during and after the infusion and administer premedications, such as antihistamines, corticosteroids, and acetaminophen, as prescribed.
Gastrointestinal toxicity and hepatotoxicity are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Gastrointestinal toxicity and hepatotoxicity may be caused by other drugs, such as methotrexate and cyclophosphamide, which are often used in combination with rituximab. The nurse should monitor the client's liver function tests, such as serum bilirubin, alkaline phosphatase, and transaminases, and report any abnormalities to the provider.
Hypertension and bleeding are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Hypertension and bleeding may be caused by other factors, such as renal impairment, coagulation disorders, or anticoagulant therapy. The nurse should monitor the client's blood pressure, urine output, creatinine clearance, coagulation studies, platelet count, and signs of bleeding.
Flulike symptoms and bone marrow suppression are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Flulike symptoms and bone marrow suppression may be caused by other drugs, such as interferon alfa and vinblastine, which are also used to treat nonHodgkin's lymphoma. The nurse should monitor the client's temperature, white blood cell count, hemoglobin level, and symptoms of infection or anemia.
Choice A reason:
Infusion reactions and allergic reactions are common and potentially serious adverse effects of rituximab, a monoclonal antibody that binds to the CD20 antigen on the surface of B lymphocytes and causes their destruction. Rituximab is used to treat nonHodgkin's lymphoma, a type of cancer that affects the lymphatic system. Infusion reactions can occur during or shortly after the administration of rituximab and may include fever, chills, rigors, hypotension, dyspnea, bronchospasm, angioedema, and anaphylaxis. Allergic reactions can occur within hours or days after the infusion and may include rash, urticaria, pruritus, and serum sickness. The nurse should monitor the client's vital signs, oxygen saturation, and symptoms during and after the infusion and administer premedications, such as antihistamines, corticosteroids, and acetaminophen, as prescribed.
Choice B reason:
Gastrointestinal toxicity and hepatotoxicity are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Gastrointestinal toxicity and hepatotoxicity may be caused by other drugs, such as methotrexate and cyclophosphamide, which are often used in combination with rituximab. The nurse should monitor the client's liver function tests, such as serum bilirubin, alkaline phosphatase, and transaminases, and report any abnormalities to the provider.
Choice C reason:
Hypertension and bleeding are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Hypertension and bleeding may be caused by other factors, such as renal impairment, coagulation disorders, or anticoagulant therapy. The nurse should monitor the client's blood pressure, urine output, creatinine clearance, coagulation studies, platelet count, and signs of bleeding.
Choice D reason:
Flulike symptoms and bone marrow suppression are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Flulike symptoms and bone marrow suppression may be caused by other drugs, such as interferon alfa and vinblastine, which are also used to treat nonHodgkin's lymphoma. The nurse should monitor the client's temperature, white blood cell count, hemoglobin level, and symptoms of infection or anemia.